ResearcherThe Ohio State UniversityActive in the last 2 years
Wancai Yang
Matched on ORCID iD 0000-0001-7437-9197; OpenAlex author ID A5074110801. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 0, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 19
2024: 2 papers · 2025: 1 paper
Papers 3
- Prognostic significance of serum MUC5AC in resected pancreatic ductal adenocarcinoma: initial insights. Last author DOI 10.3389/fonc.2025.1544928↗
- Serum MUC5AC Predicts Recurrence in Pancreatic Ductal Adenocarcinoma Patients on Neoadjuvant Chemotherapy Last author DOI 10.20944/preprints202409.0945.v1↗
- Mature MUC5AC Expression in Resected Pancreatic Ductal Adenocarcinoma Predicts Treatment Response and Outcomes. Co-author DOI 10.3390/ijms25169041↗
Closest collaborators
The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Upender Manne Manne · 3 shared papers, 2024–2025 · strength 0.51
- Paper Prognostic significance of serum MUC5AC in resected pancreatic ductal adenocarcinoma: initial insights. DOI 10.3389/fonc.2025.1544928↗
- Paper Mature MUC5AC Expression in Resected Pancreatic Ductal Adenocarcinoma Predicts Treatment Response and Outcomes. DOI 10.3390/ijms25169041↗
- Paper Serum MUC5AC Predicts Recurrence in Pancreatic Ductal Adenocarcinoma Patients on Neoadjuvant Chemotherapy DOI 10.20944/preprints202409.0945.v1↗
- Kannan Thanikachalam · 3 shared papers, 2024–2025 · strength 0.51
- Paper Prognostic significance of serum MUC5AC in resected pancreatic ductal adenocarcinoma: initial insights. DOI 10.3389/fonc.2025.1544928↗
- Paper Mature MUC5AC Expression in Resected Pancreatic Ductal Adenocarcinoma Predicts Treatment Response and Outcomes. DOI 10.3390/ijms25169041↗
- Paper Serum MUC5AC Predicts Recurrence in Pancreatic Ductal Adenocarcinoma Patients on Neoadjuvant Chemotherapy DOI 10.20944/preprints202409.0945.v1↗
- Ashwini Kumar Esnakula · 3 shared papers, 2024–2025 · strength 0.51
- Paper Prognostic significance of serum MUC5AC in resected pancreatic ductal adenocarcinoma: initial insights. DOI 10.3389/fonc.2025.1544928↗
- Paper Mature MUC5AC Expression in Resected Pancreatic Ductal Adenocarcinoma Predicts Treatment Response and Outcomes. DOI 10.3390/ijms25169041↗
- Paper Serum MUC5AC Predicts Recurrence in Pancreatic Ductal Adenocarcinoma Patients on Neoadjuvant Chemotherapy DOI 10.20944/preprints202409.0945.v1↗
- Lianbo Yu · 3 shared papers, 2024–2025 · strength 0.51
- Paper Prognostic significance of serum MUC5AC in resected pancreatic ductal adenocarcinoma: initial insights. DOI 10.3389/fonc.2025.1544928↗
- Paper Mature MUC5AC Expression in Resected Pancreatic Ductal Adenocarcinoma Predicts Treatment Response and Outcomes. DOI 10.3390/ijms25169041↗
- Paper Serum MUC5AC Predicts Recurrence in Pancreatic Ductal Adenocarcinoma Patients on Neoadjuvant Chemotherapy DOI 10.20944/preprints202409.0945.v1↗
- Ankur Sheel · 3 shared papers, 2024–2025 · strength 0.51
- Paper Prognostic significance of serum MUC5AC in resected pancreatic ductal adenocarcinoma: initial insights. DOI 10.3389/fonc.2025.1544928↗
- Paper Mature MUC5AC Expression in Resected Pancreatic Ductal Adenocarcinoma Predicts Treatment Response and Outcomes. DOI 10.3390/ijms25169041↗
- Paper Serum MUC5AC Predicts Recurrence in Pancreatic Ductal Adenocarcinoma Patients on Neoadjuvant Chemotherapy DOI 10.20944/preprints202409.0945.v1↗
- Ashish Manne · 3 shared papers, 2024–2025 · strength 0.51
- Paper Prognostic significance of serum MUC5AC in resected pancreatic ductal adenocarcinoma: initial insights. DOI 10.3389/fonc.2025.1544928↗
- Paper Mature MUC5AC Expression in Resected Pancreatic Ductal Adenocarcinoma Predicts Treatment Response and Outcomes. DOI 10.3390/ijms25169041↗
- Paper Serum MUC5AC Predicts Recurrence in Pancreatic Ductal Adenocarcinoma Patients on Neoadjuvant Chemotherapy DOI 10.20944/preprints202409.0945.v1↗
- Jordan M. Cloyd · 3 shared papers, 2024–2025 · strength 0.51
- Paper Prognostic significance of serum MUC5AC in resected pancreatic ductal adenocarcinoma: initial insights. DOI 10.3389/fonc.2025.1544928↗
- Paper Mature MUC5AC Expression in Resected Pancreatic Ductal Adenocarcinoma Predicts Treatment Response and Outcomes. DOI 10.3390/ijms25169041↗
- Paper Serum MUC5AC Predicts Recurrence in Pancreatic Ductal Adenocarcinoma Patients on Neoadjuvant Chemotherapy DOI 10.20944/preprints202409.0945.v1↗
- Anup Kasi · 3 shared papers, 2024–2025 · strength 0.51
- Paper Prognostic significance of serum MUC5AC in resected pancreatic ductal adenocarcinoma: initial insights. DOI 10.3389/fonc.2025.1544928↗
- Paper Mature MUC5AC Expression in Resected Pancreatic Ductal Adenocarcinoma Predicts Treatment Response and Outcomes. DOI 10.3390/ijms25169041↗
- Paper Serum MUC5AC Predicts Recurrence in Pancreatic Ductal Adenocarcinoma Patients on Neoadjuvant Chemotherapy DOI 10.20944/preprints202409.0945.v1↗
- Ravi Kumar Paluri · 3 shared papers, 2024–2025 · strength 0.51
- Paper Prognostic significance of serum MUC5AC in resected pancreatic ductal adenocarcinoma: initial insights. DOI 10.3389/fonc.2025.1544928↗
- Paper Mature MUC5AC Expression in Resected Pancreatic Ductal Adenocarcinoma Predicts Treatment Response and Outcomes. DOI 10.3390/ijms25169041↗
- Paper Serum MUC5AC Predicts Recurrence in Pancreatic Ductal Adenocarcinoma Patients on Neoadjuvant Chemotherapy DOI 10.20944/preprints202409.0945.v1↗
- Deepak Sherpally · 2 shared papers, 2024–2025 · strength 0.36
- Sameek Roychowdhury · 2 shared papers, 2024 · strength 0.31
- Mary E. Dillhoff · 2 shared papers, 2024 · strength 0.31
- Anne M. Noonan · 2 shared papers, 2024 · strength 0.31
- Aslam M. Ejaz · 2 shared papers, 2024 · strength 0.31
- Shafia Rahman · 2 shared papers, 2024 · strength 0.31
- Timothy Michael Pawlik · 1 shared paper, 2025 · strength 0.21
- Davendra P. S. Sohal · 1 shared paper, 2024 · strength 0.15
- Eric David Miller · 1 shared paper, 2024 · strength 0.15
- Kenneth L Pitter · 1 shared paper, 2024 · strength 0.15
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.